The ExAblate MR-guided focused ultrasound system from InSightec of Tirat Carmel, Israel, is being used for the first time for the treatment of prostate cancer patients.
Seven patients with localized low-risk prostate cancer have been treated in clinical trials at the N.N. Petrov Research Institute of Oncology in St. Petersburg, Russia, and at the National Cancer Centre at the Singapore General Hospital in Singapore.
The ExAblate system has been in clinical use globally for the treatment of uterine fibroids; it's also in use outside of the U.S. for bone metastases.
Related Reading
InSightec gets Japanese clearance, January 13, 2010
Study: InSightec's ExAblate helps with pain, July 14, 2009
InSightec notches $15 million investment, March 19, 2009
InSightec raises $30 million, November 30, 2007
InSightec proceeds with phase I trial, September 26, 2007
Copyright © 2010 AuntMinnie.com
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=100&w=100&auto=format%2Ccompress&q=70)
.fFmgij6Hin.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
